Cantargia

Edison Investment Research has terminated coverage on Cantargia (CANTA). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

Equities

Equities by Sector

Sectors

Thematics

Latest

Stock of the month – March

Edison and Aquis: Insights from Aquis class of 2025 celebration

Edison explains: AI for insurance brokers and platforms – threat or opportunity?

Audiovisual

Latest

Take on trusts – March 2026

YXT.com – executive interview

Greggs – executive interview

About Edison

Corporates

Investors

Careers

Cantargia (OMX: CANTA)

Latest Insights

Cantargia (OMX: CANTA) granted new US patent

Cantargia (OMX: CANTA): CAN10 programme acquired by Otsuka

Cantargia (OMX: CANTA) – Nadunolimab receives FDA Fast Track designation

Cantargia (OMX: CANTA) enrols first patient in leukaemia study

Sector

Equity Analyst

Key Management

Research

Cantargia — Announcement of rights issue

Cantargia — ASCO data do not disappoint

Cantargia – executive interview

Cantargia — CAN04 progressing on all fronts

Cantargia — Useful insights from CANOPY-1 data

Cantargia – executive interview

Cantargia: Edison Open House Healthcare 2022

Cantargia — ‘Post-Novartis’ era has begun

Cantargia – executive interview

Cantargia — Sentiment affected, but fundamentals robust

Cantargia – executive interview

Cantargia — Novartis’s CANOPY-2 trial disappoints

Cantargia – Edison Open House interview

Cantargia — Buoyant on CANFOUR and CANOPY interims

Cantargia — Great equity story underpins large share issue

Executive interview – Cantargia

Cantargia — Excellent end to the year

Cantargia — CANFOUR study on track, US trial preparations

Cantargia — Full Phase I data presented at ASCO

Cantargia — Signs of growing interest in IL-1 pathway targets

Executive interview – Cantargia

Cantargia — Nidanilimab transitioning to Phase IIa

Cantargia — CANFOUR interim Phase I presented at ESMO

Cantargia — Phase IIa set to start in Q418

Cantargia — Tackling tumour promoting inflammation

Outlook for 2024: Life sciences – where has the conviction gone?

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

VolitionRx – Decoding the DNA of cancer

ASCO 2023 key takeaways

Machine learning in drug development

Outlook for 2023: Biotechs remain central to novel drug development

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

Cell and gene therapies

Drug delivery platforms

Oncology ABCs (part three) – thinking outside the box in women’s cancer

Neuroscience comeback

IPO apocalypse

Oncology ABCs (part two) – vaccines: niche no longer

ESG, moving beyond the box tick

Oncology ABCs (part one) – a small-cap biopharma prospectus series

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

Artificial intelligence in drug discovery

Biosynthesis – Taking the cannabinoid market to new heights

Seven things every investor should know about SIGA technologies & biological weapons

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

Edison Exhibits- antibiotic development

The next wave in AMD

The A-B-T of biosimilars- Explaining contemporary life science issues

Cannabinoid Therapies- The coming retail wave

Cannabinoid Therapies- Therapeutics turning a corner

Trial outcomes and value – Explaining contemporary clinical trial issues

Drug pricing – Market access and reimbursement

The diagnostics sector